# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
23andMe Holding (NASDAQ:ME) reported quarterly losses of $(0.14) per share. The company reported quarterly sales of $40.000 mi...
Special Committee Reviewing Proposal With Wells Fargo As Financial Advisor And Dechert LLP As Legal Advisor
The focus of the Lung Cancer Genetics Study is to better understand the genetics of people with lung cancer in order to improve...
As part of the pilot, 23andMe will offer up to 5,000 23andMe+ Premium and Total Health members the opportunity to receive blood...
- Reuters